Mind Medicine Mindmed Inc (MNMD)
$8.52
0.00 (0.00%)
MNMD Stock Quote Delayed 30 Minutes
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to take a look at the biggest pre-market stock movers for Thursday and the news that's got those shares moving!
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
651,475
Day's Range
$8.36 - $8.76
52-Week Range
$2.41 - $12.22
Dividend & Yield
N/A (N/A)
MNMD Stock Predictions, Articles, and Mind Medicine Mindmed Inc News
FDA Greenlight Sets the Stage for Upside With Mind Medicine
Few catalysts can move healthcare stocks like a regulatory clearance can - and MNMD stock could be 2022's top psychedelics-sector investment.
MNMD Stock: The FDA Go-Ahead That Has MindMed Investors Feeling Euphoric Today
MindMed (MNMD) stock is getting a buzz today thanks to approval from the FDA to move forward with a clinical trial of MM-120.
MNMD Stock: The Latest Psychedelic Drug News MindMed Fans Should Watch
MindMed's LSD trials are facing a regulatory roadblock but MNMD stock isn't being forced down. Here's why investors should watch.
MNMD Stock Pops Higher After MindMed Unveils ‘Psychedelic’ Data
MNMD stock is up today after MindMed reported positive findings on the interactions between psilocybin and an antidepressant.
Push the Boundaries of DMT Therapy with Mind Medicine
Ready to explore an under-developed area of psychedelic medicine? If so, then consider a long position in low-priced MNMD stock.
No Matter How the Pandemic Rolls, Mind Medicine Will Prevail
While MNMD stock is controversial due to its underlying psychedelic therapies, the broader narrative is exceptionally compelling.
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
So what did the stock market do today? All eyes were on hard-hit Nikola stock and growing interest in mental health startups.
Mind Medicine Has More Obstacles Than Opportunities
MNMD stock could revolutionize mental healthcare with its novel therapeutics, but there are currently too many risks with its business.
MindMed Stock Is Overvalued and Too Risky to Own
MindMed can be the future of psychedelic medicines, but without cash flow from revenue, MNMD stock is nothing to get excited about.
The MindMed Psychedelic Revolution Will Take Years to Come to Fruition
MNMD stock aspires to be a lot to many but could flop. Prices are low, risk is high and speculators could become savants.
Get a Dose of Innovative Science With Mind Medicine
MNMD stock ran high last year, but the story is still being written as Mind Medicine marks progress with its psychedelics-based treatments.
